Drug Profile
Eicosapentaenoic acid - SLA Pharma
Alternative Names: ALFA; EPA-FFA - SLA Pharma; EPA-FFA gastro-resistant capsules - SLA Pharma; EPAspire™Latest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator SLA Pharma
- Developer SLA Pharma; University of Bologna
- Class Antihyperlipidaemics; Eicosanoids; Omega 3 fatty acids; Small molecules
- Mechanism of Action Arachidonic acid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III COVID 2019 infections; Familial adenomatous polyposis
- Phase I/II Colorectal cancer; Ulcerative colitis
- No development reported Crohn's disease; Intestinal polyps
Most Recent Events
- 08 Jan 2021 Phase-III clinical trials in COVID-2019 infections (In adults, In the elderly) in Spain (PO) (NCT04335032) (EudraCT2020-001396-33)
- 08 Jan 2021 Phase-III clinical trials in COVID-2019 infections (In adults, In the elderly) in United Kingdom (PO) (NCT04335032) (EudraCT2020-001396-33)
- 14 Apr 2020 KD Pharma and SLA Pharma file an IND application with the US FDA for COVID-2019 infections related symptoms